Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Status Completed

Clinical Trial Summary

This phase II trial is studying how well sorafenib works in treating patients with extensive stage small cell lung cancer. Sorafenib may stop the growth of small cell lung cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of BAY 43-0006 in previously-treated, platinum-sensitive and platinum-refractory patients with measurable disease and extensive stage small cell lung cancer (E-SCLC) in terms of response rate (confirmed and unconfirmed, complete and partial).

SECONDARY OBJECTIVES:

I. To assess the qualitative and quantitative toxicities of BAY 43-9006 in this patient population.

II. To assess overall survival in this group of patients treated with BAY 43-9006.

III. To collect specimens via the Lung Cancer Specimen Repository Protocol (S9925) in order to perform exploratory analyses of the relationship between selected markers and patient outcomes.

OUTLINE: This is a multicenter study. Patients are stratified according to platinum sensitivity status (platinum sensitive vs platinum refractory).

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for up to 2 years from study entry. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00182689
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	July 2005
Completion date	October 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05903092` - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT01935336` - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers	Phase 2
Completed	`NCT00544596` - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT04063163` - A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Phase 3
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Completed	`NCT00773955` - R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00528645` - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer	Phase 2
Recruiting	`NCT05468489` - To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC	Phase 2
Active, not recruiting	`NCT00828139` - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Phase 2
Recruiting	`NCT05896059` - A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC	Phase 2
Recruiting	`NCT04346914` - Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer	Phase 1
Recruiting	`NCT06323265` - A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Withdrawn	`NCT01325753` - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body	N/A
Completed	`NCT00019006` - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer	Phase 1
Not yet recruiting	`NCT04933175` - Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer	Phase 2
Recruiting	`NCT02972320` - Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic	Phase 2
Completed	`NCT01331525` - The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1
Terminated	`NCT00088933` - Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer	Phase 1
Completed	`NCT00020202` - FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer	Phase 2